X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin, which is being evaluate for the treatment of duchenne muscular dystrophy.
Lead Product(s): RGX-202
Therapeutic Area: Genetic Disease Product Name: RGX-202
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin. It is being developed for the treatment of duchenne muscular dystrophy in patients with ages 4 to 11 years old.
Lead Product(s): RGX-202
Therapeutic Area: Genetic Disease Product Name: RGX-202
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Under the agreement, Merck will receive an exclusive license to RGX-202 (ompenaclid), currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer, outside of the United States and an option to co-develop and co-promote ompenaclid in the US.
Lead Product(s): RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: RGX-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: $45.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
RGX-202 is a Cell and Gene therapy drug infused intravenously for the treatment of Duchenne Muscular Dystrophy, transferring the micro-dystrophin gene.
Lead Product(s): RGX-202
Therapeutic Area: Genetic Disease Product Name: RGX-202
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
RGX-202 delivers a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal domain found in naturally occurring dystrophin, leading to improved muscle resistance to contraction-induced muscle damage in dystrophic patients.
Lead Product(s): RGX-202
Therapeutic Area: Genetic Disease Product Name: RGX-202
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
RGX-202, delivers a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal domain found in naturally occurring dystrophin, leading to improved muscle resistance to contraction-induced muscle damage in dystrophic patients.
Lead Product(s): RGX-202
Therapeutic Area: Genetic Disease Product Name: RGX-202
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Data highlights clinical activity in patients with advanced colorectal (CRC) tumors from a clinical trial of RGX-202, a first-in-class small molecule that inhibits a novel cancer metabolism pathway involved in supplying energy to cancer cells.
Lead Product(s): RGX-202
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
